ClinicalTrials.gg
TerminatedNCT04541602NMCiCIPUpdated Dec 12, 2024

Detection of Neuromuscular Complications in Critically Ill Patients

An observational study in Critical Illness, Dysphagia and Intensive Care Unit Acquired Weakness, sponsored by University of Rostock. Terminated at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-12.

Primary conditionDeglutition DisordersRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Deglutition Disorders
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Deglutition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rostock · Observational

How we know

Why this study was terminated
PI and the majority of the study team left institution.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
5
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Deglutition Disorders with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Deglutition Disorders · Germany.

Started
2020
the only one that year
Observational
9 of 27
4 open now
Registered
20th of 27
by date
Lead sponsor
2 of 27
University of Rostock

Among the 27 studies in Deglutition Disorders with a site in Germany, this one is the only one that started in 2020, is one of 9 observational ones, and was the 20th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

6 of the 27 studies in Deglutition Disorders with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Deglutition Disorders with a site in Germany, or all of them as a file.
02

Study summary

Dysphagia and the intensive care unit-acquired weakness (ICU-AW) are common and outcome-relevant neuromuscular complications in critically ill patients, especially after prolonged mechanical ventilation, sepsis and multi-organ failure. However, the impact of these two complications on the clinical course of critically ill patients needs further investigation.

Furthermore, the standard diagnostic procedure to detect and grade the acquired dysphagia using the fiberoptic endoscopic evaluation of swallowing (FEES) and the Medical Research Council sum score (MRC-ss) to detect ICU-AW are time-consuming and strongly dependent on patient compliance. An early and easy-to-use detection of these neuromuscular complications is currently difficult to be achieved in this patient population.

Neuromuscular ultrasound (NMUS) and the measurement of neuromuscular damage blood biomarkers became increasingly interesting for clinical researchers in the recent years due to their broad availability and their simple and non-invasive application. However, the value of these new diagnostic tests to evaluate dysphagia and ICU-AW needs to be verified.

Read the detailed description

In this single-center observational study the investigators aim to evaluate neuromuscular ultrasound and blood biomarkers of neuromuscular damage as innovative diagnostic features for the detection, monitoring and prognostication of dysphagia and ICU-AW in critically ill patients. A detailed neurological examination, NMUS as well as blood biomarker measurements (e.g. Myl3, TNNI1, FABP-3) will be longitudinally performed at study day 1 (day of study inclusion), day 3, day 10 and day 17 after study inclusion. The neurological examination comprises the use of validated scales (GCS, RASS, mRS) and scores (MRC-ss) to assess consciousness, neurological disability and muscle strength as well as the the examination of the reflex status. Using a standardized in-house NMUS protocol the facial (masseter muscle), submental (digastricus muscle, mylohyoid muscle), cervical (sternocleidomastoid muscle) and extremity muscles (biceps brachii, brachiradialis, quadriceps femoris, tibialis anterior) as well as the vagus nerve will be assessed repeatedly. Additionally, a FEES as the current gold standard diagnostic for dysphagia will be performed at study day 10 or as soon as possible (depending on the ability of the patient to cooperate with the examiner) after study day 10 to detect and grade the dysphagia.

All study participants will be reevaluated at day 90 after study inclusion with regard to functional disability and survival.

Furthermore, healthy volunteers will be recruited and assessed in the same way as patients including a clinical examination, NMUS, laboratory testing and FEES.

The investigators hypothezise that:

  • acquired dysphagia due to critical illness (not caused by central nervous system damage) is more likely in patients with ICU-AW
  • the outcome in patients with a combination of ICU-AW and dysphagia is worse compared to patients with only one of these entities
  • NMUS is able to detect and monitor dysphagia and ICU-AW in critically ill patients who are at risk of neuromuscular dysfunction
  • specific blood biomarker levels correlate with the severity of neuromuscular impairment and are of value to identify patients with ICU-AW and acquired dysphagia
03

Conditions studied

  • Critical Illness
  • Dysphagia
  • Intensive Care Unit Acquired Weakness
  • Neuromuscular Diseases

Browse trials for

04

In context

Deglutition Disorders Reclassified

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's enrollment of 5 is below the median of 91 across 250 observational studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.

Compared within Deglutition Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients admitted to the intensive care units of the study center will be screened for study eligibility according to the inclusion and exclusion criteria. Additionally, healthy volunteers will be recruited to participate as controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients above 17 years of age
  • Sequential organ failure assessment (SOFA) score ≥8 within the first two days after ICU admission
  • invasive mechanical ventilation ≥48 hours

Exclusion criteria

Exclusion Criteria:

  • no written from patient or legal representative
  • participation in another interventional study
  • patient transfer from another hospital (>1 day hospital stay)
  • preexisting swallowing disorder or disease of the larynx, pharynx or esophagus
  • previous surgery of the larynx, pharynx, esophagus or maxillofacial surgery
  • preexisting neuromuscular diseases
  • preexisting central nervous system diseases (stroke, hemorrhage, tumor, traumatic brain injury, brain surgery, epilepsy, hydrocephalus)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
5 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Dysphagia-positive

    * critically ill patients more than 17 years of age * matching study inclusion criteria * confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later * ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)

  • Dysphagia-negative

    * critically ill patients more than 17 years of age * matching study inclusion criteria * newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later * ICU-AW positive (MRC-ss \<48) or ICU-AW negative (MRC-ss ≥48)

  • Controls

    * healthy volunteers without any neuromuscular disease * swallowing dysfunction ruled out using FEES

07

What researchers measure

Primary outcomes

  1. Incidence of sensomotory dysphagia in critically ill patients with and without intensive care unit-acquired weakness as well as controls

    Assessment of dysphagia and ICU-AW using validated diagnostics (FEES, NMUS) and scores (MRC-ss)

    Time frame: Day 90

  2. Changes in ultrasonographic parameters between patients with and without newly acquired sensomotory dysphagia as well as controls

    NMUS protocol performed at study days 1, 3, 10 and 17

    Time frame: Change from baseline ultrasound parameters at day 17

  3. Change in neuromuscular damage blood biomarker levels in critically ill patients with and without newly acquired sensomotory dysphagia as well as controls

    Specific blood biomarker levels (e.g. TNNI1, FABP-3) measured at study days 1, 3, 10 and 17

    Time frame: Change from baseline parameters at day 17

Secondary outcomes

  1. Quality of life in patients with and without neuromuscular complications after hospital discharge

    Assessment of the overall quality of life using validated tests \[e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)\]

    Time frame: Day 90

  2. Length of hospital stay comparing critically ill patients with and without neuromuscular complications

    Cumulative days in hospital

    Time frame: 1 year

  3. Survival in critically ill patients with and without neuromuscular complications

    Survival after 28 days

    Time frame: Day 28

  4. Survival in critically ill patients with and without neuromuscular complications

    Survival after 90 days

    Time frame: Day 90

08

Study locations

1 site
  • Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock
    Rostock, Mecklenburg-Vorpommern 18057, Germany
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2024, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 9, 2020
StartActual
Sep 1, 2020
Primary completionActual
Dec 8, 2024
CompletionActual
Dec 8, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04541602
Lead sponsor
University of Rostock
Responsible party
Dr. Johannes Ehler, MD (PD Dr. med. Johannes Ehler, MD, University of Rostock) — Principal investigator
First posted
Sep 9, 2020
Start date
Sep 1, 2020
Primary completion
Dec 8, 2024
Completion
Dec 8, 2024
Last update
Dec 12, 2024

Study contacts

Felix Klawitter, MD
principal investigator · University of Rostock
Johannes Ehler, MD
principal investigator · University of Rostock

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion